Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV

Sponsor
University Hospital, Basel, Switzerland
Study ID
NCT00429962
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - 95 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This pilot study is designed to evaluate the safety and efficacy of intravitreal ranibizumab used in combination with verteporfin photodynamic therapy (Visudyne®) compared to ranibizumab monotherapy for the treatment of subfoveal CNV secondary to AMD

Key Dates

First listed
Feb 1, 2007
Start date
Jul 31, 2006
Status verified
Apr 2009
Primary completion
Jun 30, 2008
Completion
Jun 30, 2008

Study Design

Enrollment
40 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: A
    intravitreal ranibizumab used in combination with verteporfin photodynamic therapy
  • Active Comparator: B
    intravitreal ranibizumab

Primary Outcome Measure

First injection with PDT [ Time Frame: monthly ]

Related Studies